Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.

@article{Xu2012MolecularMO,
  title={Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.},
  author={Hongtao Xu and Maureen Oliveira and Eugene Lekeawung Asahchop and Matthew McCallum and Peter Kojo Quashie and Yingshan Han and Yudong Quan and Mark A. Wainberg},
  journal={Journal of virology},
  year={2012},
  volume={86 23},
  pages={12983-90}
}
Etravirine (ETR) is an expanded-spectrum nonnucleoside reverse transcriptase inhibitor (NNRTI) approved for use as an antiretroviral agent in treatment-experienced patients. Y181C and E138K in HIV-1 RT are among 20 different drug resistance mutations associated with ETR. However, E138K can be consistently selected by ETR when wild-type viruses but not viruses containing Y181C are grown in tissue culture. This study was carried out to evaluate any possible mechanisms that might explain… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
11 Citations
52 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes

  • EL Asahchop
  • Antimicrob. Agents Chemother
  • 2011
Highly Influential
7 Excerpts

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery

  • PA Janssen
  • rilpivirine). J. Med
  • 2005
Highly Influential
6 Excerpts

Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection

  • JD Croxtall
  • Drugs
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…